[Brentuximab vedotin and cord blood transplantation for primary refractory Hodgkin lymphoma following autologous hematopoietic stem cell transplantation]

Rinsho Ketsueki. 2015 Jun;56(6):699-704. doi: 10.11406/rinketsu.56.699.
[Article in Japanese]

Abstract

We report a 26-year-old man with primary refractory nodular sclerosis Hodgkin lymphoma against ABVD, ICE and autologous peripheral blood stem cell transplantation (auto-PBSCT), presenting with multiple epidural spinal cord compressions, paraplegia, and generalized lymphadenopathy. We administrated four cycles of brentuximab vedotin to achieve a complete response, and then conducted cord blood transplantation. This case raises the possibility of a new strategy for refractory Hodgkin lymphoma showing residual lesions after auto-PBSCT.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Brentuximab Vedotin
  • Fetal Blood / transplantation*
  • Hematopoietic Stem Cell Transplantation
  • Hodgkin Disease / therapy*
  • Humans
  • Immunoconjugates / therapeutic use*
  • Male
  • Recurrence
  • Transplantation, Autologous
  • Treatment Outcome

Substances

  • Immunoconjugates
  • Brentuximab Vedotin